Thomas Castellano
Director of Finance/CFO at ABZENA PLC
Net worth: 708 165 $ as of 2024-03-30
Profile
Presently, Thomas P. Castellano is Global Vice President-Operational Finance at Catalent, Inc. He is also on the board of Catalent France Beinheim SA. Mr. Castellano received an undergraduate degree and an MBA from Seton Hall University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
CATALENT INC
0.01% | 2023-12-03 | 12,545 ( 0.01% ) | 708 165 $ | 2024-03-30 |
Thomas Castellano active positions
| Companies | Position | Start |
|---|---|---|
| ABZENA PLC | Director of Finance/CFO | 2023-06-04 |
Catalent France Beinheim SA
 Catalent France Beinheim SA Pharmaceuticals: MajorHealth Technology Catalent France Beinheim SA is engaged in softgel development and manufacturing operations. It offers formulation development and manufacturing services for controlled substances, highly potent compounds, and hormones. The firm’s technologies include optiform® solution suite, optigel™ bio, and rp scherer softgel technology. The company was founded on May 3, 1965 and is headquartered in Beinheim, France. | Director/Board Member | - |
| Catalent Belgium Holding SA | Director/Board Member | 2021-08-04 |
Former positions of Thomas Castellano
| Companies | Position | End |
|---|---|---|
| CATALENT, INC. | Director of Finance/CFO | 2023-04-12 |
Training of Thomas Castellano
| Seton Hall University | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| CATALENT, INC. | Health Technology |
| Private companies | 3 |
|---|---|
| Catalent Belgium Holding SA | |
Catalent France Beinheim SA
Catalent France Beinheim SA Pharmaceuticals: MajorHealth Technology Catalent France Beinheim SA is engaged in softgel development and manufacturing operations. It offers formulation development and manufacturing services for controlled substances, highly potent compounds, and hormones. The firm’s technologies include optiform® solution suite, optigel™ bio, and rp scherer softgel technology. The company was founded on May 3, 1965 and is headquartered in Beinheim, France. | Health Technology |
Abzena Ltd.
 Abzena Ltd. BiotechnologyHealth Technology Abzena Ltd. engages in the provision of proprietary technologies and complementary services to enable the development and manufacture of biopharmaceutical products. It offers antibody discover and candidate screening, immunology and immunogenicity assessment, antibody and protein engineering, bio conjugation, custom synthesis of cytotoxic payloads, reagents, and other small molecules, manufacture of payload linkers, development of manufacturing cell lines, and manufacture of biopharmaceuticals. The company was founded by Sunil Shaunak in 2001 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
- Stock Market
- Insiders
- Thomas Castellano
